Martínez GAJ, Apolonio MA, Copado MY, Acevedo GS

Language: Spanish
References: 18
Page: 37-45
PDF size: 146.37 Kb.

ABSTRACT

Congenital malformations of the circulatory system represent the second cause of infant mortality in Mexico. The joint performance of a fetal heart screening, neonatal heart screening and a thorough cardiovascular physical examination contribute to a timely diagnosis of critical congenital heart disease. This article summarizes the use of these three tools.

REFERENCES

1. Instituto Nacional de Estadística y Geografía (INEGI): Registros de mortalidad. Consulta en línea: principales causas de mortalidad por residencia habitual, grupos de edad y sexo del fallecido, 2021. Disponible en: https://www.inegi.org.mx/programas/mortalidad/default.html#Tabulados

2. Torres-Cosme JL, Rolón Porras C, Aguinaga RM et al. Mortality from congenital heart disease in Mexico: a problem on the rise. PLoS One. 2016; 11(3): 1-16

3. Eckersley L, Saddler L, Parry E et al. Timing of diagnosis affects mortality in critical congenital heart disease. Arch Dis Child. 2016; 101 (6): 516-520.

4. Carvalho JS, Mavrides E, Shinebourne EA, Campbell S, Thilaganathan B. Improving the effectiveness of routine prenatal screening for major congenital heart defects. Heart. 2002; 88 (4): 387-391.

5. Donofrio MT, Moon-Grady AJ, Hornberger LK et al. Diagnosis and treatment of fetal cardiac disease. Circulation. 2014; 129: 2183-2242.

6. Carvalho JS, Moscoso G, Ville Y. First trimester transabdominal fetal echocardiography. Lancet. 1998; 351: 1023-1027.

7. Favre RY, Cherif M, Kohler A et al. The role of fetal nuchal translucency and ductus venosus Doppler at 11-14 weeks of gestation in the detection of major congenital heart defects. Ultrasound Obstet Gynecol. 2003; 21 (3): 239-243.

8. Maiz N, Plasencia W, Dagklis T, Faros E, Nicolaides K. Ductus venosus Doppler in fetuses with cardiac defects and increased nuchal translucency thickness. Ultrasound Obstet Gynecol. 2008; 31 (3): 256-260.

9. Persico N, Moratalla J, LombardiI CM, Zidere V, Allan L, Nicolaides KH. Fetal echocardiography at 11-13 weeks by transabdominal high-frequency ultrasound. Ultrasound Obstet Gynecol. 2011; 37: 296-301.

10. Copado MDY, Martínez GAJ, Acevedo GS. Importancia del diagnóstico prenatal de las cardiopatías congénitas. Perinatol Reprod Hum. 2018; 32: 127-130.

11. Carvalho JS. Antenatal diagnosis of critical congenital heart disease. Optimal place of delivery is where appropriate care can be delivered. Arch Dis Child. 2016; 101 (6): 505-507.

12. Carvalho JS, Prefumo F, Ciardelli V, Sairam S, Bhide A, Shinebourne EA. Evaluation of fetal arrhythmias from simultaneous pulsed wave Doppler in pulmonary artery and vein. Heart. 2007; 93: 1448-1453.

13. Jaeggi ET, Carvalho JS, De Groot E, et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol. Circulation. 2011; 124: 1747-1754.

14. Kemper AR, Mahle WT, Martin GR et al. Strategies for implementing screening for critical congenital heart disease. Pediatrics. 2011; 128: e1259-1267.

15. Hoffman JI. Is pulse oximetry useful for screening neonates for critical congenital heart disease at high altitudes? Pediatr Cardiol. 2016; 37: 812-817.

16. De Rubens J, Mier M, Jiménez M, García H. Tamizaje neonatal cardiaco en México, una herramienta para el diagnóstico temprano de cardiopatías críticas. Gac Med Mex. 2022; 158: 67-71.

17. Singh Y. Evaluation of a child with suspected congenital heart disease. Paediatrics and Child Health. 2018; 28 (12): 556-561.

18. Artman M, Mahony L, Teitel DF. Neonatal Cardiology. 2 ed. Chapter 5: Initial evaluation of the newborn with suspected cardiovascular disease. McGraw-Hill. 2011, 75-88.